tirzepatide help with inflammation in the body and Joint Inflammation: What Evidence Shows Semaglutide/Tirzepatide: Beyond Weight Loss: Shamsah

Cardiologists prescribing GLP-1 for cardiovascular indication patients adds an entirely new prescriber base to what was previously an endocrinology and primary care domain

The transcriptomic divergence could simply reflect the difference between acute chemical shock and steady-state adaptation

Alternatives to Mounjaro include: Other GLP-1 agonists , such as Ozempic (semaglutide), Wegovy (semaglutide), Rybelsus (semaglutide), Trulicity (dulaglutide), Victoza (liraglutide), and Saxenda (liraglutide) DPP-4 Inhibitors , such as Januvia (sitagliptin), Onglyza (saxagliptin), and Tradjenta (linagliptin) SGLT2 Inhibitors , such as Invokana (canagliflozin) and Jardiance (empagliflozin) Biguanides , such as Glucophage (metformin) Sulfonylureas , such as Glucotrol (glipizide), Diabeta (glyburide), and Amaryl (glimepiride) Thiazolidinediones , such as Actos (pioglitazone) and Avandia (rosiglitazone) Generic versions of these drugs could help save on costs

Current prescribing restrictions, which are largely based on BMI thresholds or weight-loss targets, may not be appropriate, as patients with established cardiovascular disease might benefit regardless of their weight-loss response